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Spinal muscular atrophy treatment via targeting smn2 catalytic core
Abstract
The present invention is directed to methods and compositions for blocking the effect of the intronic
inhibitory splicing region of intron 7 of the SMN2 gene. The compositions and methods of the instant
invention include short oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target sites in the
SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed
transcript. The short target regions are 8-mers and 5-mers and also include the identification of a single
nucleotide base that is essential for initiating a long distance stearic inhibitory interactions as well as novel
targets distant from intron 7 which block the intronic inhibitory splicing of the same. These short target
regions and concomitant inhibitory blocking oligonucleotides are less expensive and easier to manufacture
and are small enough to cross the blood brain barrier.
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SPINAL MUSCULAR ATROPHY TREATMENT 
VIA TARGETING SMN2 CATALYTIC CORE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
[0001] This application claims priority under 35 U.S.C. 
§ 1 19 to provisional application Ser. No. 61/343,373 ?ledApr. 
28, 2010, herein incorporated by reference in its entirety. 
GRANT REFERENCE 
[0002] This invention Was made With government support 
under NIH Grant No. 7 R01 NS055925 awarded by the 
United States National Institutes of Health. The government 
has certain rights in the invention. 
BACKGROUND OF THE INVENTION 
[0003] Alternative splicing increases the coding potential 
of human genome by producing multiple proteins from a 
single gene (Black, D. L. 2003.Annu. Rev. Biochem. 72:291 
336). It is also associated With a groWing number of human 
diseases (Faustino, N. A., and T. A. Cooper. 2003. Genes Dev. 
17:419-437; Garcia-Blanco, M. A., et al. 2004. Nat. Biotech 
nol. 22:535-546; Pagani, E, and F. E. Baralle. 2004. Nat. Rev. 
Genet. 5:389-396). 
[0004] Spinal Muscular Atrophy (SMA) is an often-fatal 
genetic disorder resulting from the loss of the Survival Motor 
Neuron (SMN) protein encoded by the Survival Motor Neu 
ron (SMN) gene. The SMN genes, SMN1 and SMN2, are 
located on chromosome 5 and SMA is caused by the loss of 
SMN1 from both chromosomes. SMN2, While being almost 
identical to SMN1, is less effective at making the SMN pro 
tein. The severity of SMA is affected by the ef?ciency at 
Which SMN2, of Which there are several copies, produces the 
SMN protein. 
[0005] SMN1 encodes a ubiquitously expressed 38 kDa 
SMN protein that is necessary for snRNP assembly, an essen 
tial process for cell survival (Wan, L., et al. 2005. Mol. Cell. 
Biol. 25:5543-5551). A nearly identical copy of the gene, 
SMN2, fails to compensate for the loss of SMN1 because of 
exon 7 skipping, producing an unstable truncated protein, 
SMNA7 (Lorson, C. L., et al. 1998. Nat. Genet. 19:63-66). 
SMN1 and SMN2 differ by a critical C to T substitution at 
position 6 of exon 7 (C6U in transcript of SMN2) (Lorson, C. 
L., et al. 1999. Proc. Natl. Acad. Sci. USA 96:6307-6311; 
Monani, U. R., et al. 1999. Hum. Mol. Genet. 8:1177-1183). 
C6U does not change the coding sequence, but is su?icient to 
cause exon 7 skipping in SMN1. 
[0006] Current treatment for SMA consists of prevention 
and management of the secondary effect of chronic motor 
unit loss. Currently, there are no drug therapies available for 
the treatment or prevention of SMA. 
[0007] Antisense technology, used mostly for RNA doWn 
regulation, recently has been adapted to alter the splicing 
process (Kole et al., Acta Biochim Pol. (2004) 51, 373-8). 
Techniques that trick the splicing machinery to alter splicing 
of SMN2 pre-mRNAs are likely to have high therapeutic 
value. 
SUMMARY OF THE INVENTION 
[0008] The present invention is based, in part, on the dis 
covery that antisense targeting, displacement and/ or disrup 
tion of an intronic sequence in the SMN2 gene can enhance 
production of full-length SMN2 transcripts (transcripts con 
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taining exon 7) during splicing. In particular, the present 
inventors have identi?ed critical regions of the intron 7 Which 
must be included to be Work as a desirable therapeutic target. 
Accordingly, the invention is directed to effective use of 
blocking agents, targeting this critical region. According to 
the invention, Applicants have identi?ed a short target com 
prising no more than 8 nucleotides Which is effective as a 
therapeutic target. In another embodiment, Applicants have 
identi?ed a single critical base, 10C which must be targeted 
and Which interacts With distant sequences in a stearic fashion 
to repair intron splicing. Quite surprisingly, Applicants have 
found that this critical base, and sequences 5' thereof, Which 
do not include any previously knoWn target motifs Work bet 
ter than any targets discovered to date, and create the oppor 
tunity to generate sequences as short as 5-mers that are effec 
tive in repairing splicing. The invention thus includes, 
blocking oligonucleotide reagents (e.g., modi?ed antisense 
oligoribonucleotides) to inhibit these critical intronic splice 
inhibitory sequences. Treatment of cells derived from SMA 
patients With the oligonucleotide reagent compositions of the 
instant invention Will effectively restore the production of the 
full-length SMN protein. These results demonstrate for the 
?rst time a stearic distant interaction betWeen an oligonucle 
otide reagent and inhibition of an SMN2 splice site inhibitory 
domain. This distant interaction also provides a novel target 
site for inhibition of the intron 7 aberrant splicing and 
includes oligonucleotides designed to block a 10C interacting 
region of intron 7. 
[0009] Prior Work by the inventors and others had discov 
ered the ISS-Nl, CCAGCAUUAU GUUUG (SEQ ID NO:1) 
an intronic element that harbors tWo putative hnRNP A1 
binding sites (CAGCAU and UGAAAG) as a primary target 
for SMN2. Applicants here shoW that much shorter targets are 
effective, in fact even targets that do not include either of the 
hnRNP Al site, and Which include sequences Which are 5' of 
the ISS-Nl target. 
[0010] The present invention therefore is directed to com 
positions capable of blocking the inhibitory effects of the 
neWly-discovered SMN2 shortened and critical intronic 
splice silencing domain. Agents capable of blocking the 
splice-inhibitory effect of this domain have high value as 
SMA therapeutics. Featured agents capable of blocking the 
splice-inhibitory effect of the SMN2 shortened domain 
include, but are not limited to, e.g., agents that disrupt the 
interaction of an target domain-interacting protein With the 
target sequence, agents that sequester a target interacting 
protein, agents that disrupt the structure of the target domain 
and/or surrounding regions. 
[0011] In exemplary embodiments, the instant invention is 
directed to oligonucleotide reagents (e. g., modi?ed antisense 
oligoribonucleotides) that block the effect on pre-mRNA 
splicing of the SMN2 sequence via direct interaction and/or 
hybridization With the target sequence. Such RNA-comple 
mentary oligonucleotide reagents may be modi?ed by art 
recogniZed means to improve their in vivo stabilities and/or 
bioaccessibility. The instant invention also is directed to 
methods for identifying target domain-interacting proteins, 
as such methods are enabled by discovery and characteriza 
tion of the target sequence. 
[0012] In one aspect, the instant invention is directed to an 
isolated oligonucleotide reagent (e.g., an oligoribonucle 
otide) comprising a nucleotide sequence Which is comple 
mentary to an SMN2 target comprising 8 bases or even sur 
prisingly 5 or less bases in length and Which also includes the 
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critical 1OC base in the target sequence. These shorter oligo 
nucleotides are easier and less expensive to manufacture and 
are small enough to cross the blood brain barrier, making 
them especially bene?cial for use therapeutics. 
[0013] In another aspect, the instant invention is directed to 
an isolated oligonucleotide reagent (e.g., an oligoribonucle 
otide) Which is complementary to the 8mer sequence 
5'-CUGCCAGC-3'. 
[0014] In an additional aspect, the instant invention is 
directed to an isolated oligonucleotide reagent (e.g., an oli 
goribonucleotide) Which is complementary to the 5mer 
sequence 5'-GUGCC-3'. 
[0015] In a further aspect, the instant invention is directed 
to an isolated oligonucleotide reagent (e.g., an oligoribo 
nucleotide) Which is complementary to a sequence Which 
includes the 1OC and sequence 5' thereof. 
[0016] In another aspect, the instant invention is directed to 
an isolated oligonucleotide reagent (e.g., an oligoribonucle 
otide) Which is greater than 90% complementary to the 
sequence 5'-5'-CUGCCAGC-3', or GUGCC. 
[0017] In an additional aspect, the instant invention is 
directed to an isolated oligonucleotide sequence comprising 
the sequence 5'-GCUGGCAG-3'. 
[0018] In another aspect, the instant invention is directed to 
an isolated oligonucleotide sequence comprising the 
sequence 5'-GGCAG-3'. 
[0019] In another aspect, the instant invention is directed to 
an isolated oligonucleotide reagent comprising a sequence 
greater than 80% identical to the sequence 5'-GCUGGCAG 
3' or 5'-GGCAG-3'. 
[0020] In one embodiment, the oligonucleotide is modi?ed 
by the substitution of at least one nucleotide With a modi?ed 
nucleotide, such that in vivo stability is enhanced as com 
pared to a corresponding unmodi?ed oligonucleotide. In a 
related embodiment, the modi?ed nucleotide is a sugar-modi 
?ed nucleotide. In another embodiment, the modi?ed nucle 
otide is a nucleobase-modi?ed nucleotide. 
[0021] In an additional embodiment, the modi?ed nucle 
otide is a 2'-deoxy ribonucleotide. In certain embodiments, 
the 2'-deoxy ribonucleotide is 2'-deoxy adenosine or 2'-deoxy 
guanosine. In another embodiment, the modi?ed nucleotide 
is a 2'-O-methyl (e.g., 2'-O-methylcytidine, 2'-O-methylp 
seudouridine, 2'-O-methylguanosine, 2'-O-methyluridine, 
2'-O-methyladenosine, 2'-O-methyl) ribonucleotide. In an 
additional embodiment, the modi?ed nucleotide is selected 
from the group consisting of a 2'-?uoro, 2'-amino and 2'-thio 
modi?ed ribonucleotide. In a further embodiment, the modi 
?ed nucleotide is selected from the group consisting of 
2'-?uoro-cytidine, 2'-?uoro-uridine, 2'-?uoro-adenosine, 
2'-?uoro-guanosine, 2'-amino-cytidine, 2'-amino-uridine, 
2'-amino-adenosine, 2'-amino-guanosine and 2'-amino-bu 
tyryl-pyrene-uridine. In an additional embodiment, the modi 
?ed nucleotide is selected from the group consisting of 
5-bromo-uridine, 5-iodo-uridine, 5-methyl-cytidine, ribo 
thymidine, 2-aminopurine, 5-?uoro-cytidine, and 5-?uoro 
uridine, 2,6-diaminopurine, 4-thio-uridine, and 5-amino-al 
lyl-uridine. 
[0022] In a further embodiment, the modi?ed nucleotide is 
a backbone-modi?ed nucleotide. In one embodiment, the 
backbone-modi?ed nucleotide contains a phosphorothioate 
group. In another embodiment, the modi?ed nucleotide is a 
locked nucleic acid (LNA). 
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[0023] Another embodiment is directed to a composition 
comprising an oligonucleotide of the invention. In certain 
embodiments, the composition further comprises a pharma 
ceutical carrier. 
[0024] An additional embodiment of the invention is 
directed to a method of enhancing the level of exon 7-con 
taining SMN2 mRNA relative to exon-deleted SMN2 mRNA 
in a cell or cell extract, comprising contacting the cell or sell 
extract With an oligonucleotide (e. g., an oligoribonucleotide) 
of the invention, such that the level of exon 7-containing 
SMN2 mRNA relative to exon-deleted SMN2 mRNA in the 
cell or cell extract is enhanced. In one embodiment, the cell or 
cell extract is a spinal muscular atrophy (SMA) patient-de 
rived neuronal cell, muscle cell or ?broblast, or extract 
thereof. In certain embodiments, the cell or cell extract is 
selected from the group consisting of an embryonic stem cell, 
an embryonic stem cell extract, a neuronal stem cell and a 
neuronal stem cell extract. 
[0025] A related embodiment of the invention is directed to 
a method of enhancing the level of exon 7-containing SMN2 
mRNA relative to exon-deleted SMN2 mRNA in an organ 
ism, comprising administering to the organism an oligonucle 
otide of the invention (e. g., an oligoribonucleotide), such that 
the level of exon 7-containing SMN2 mRNA relative to exon 
deleted SMN2 mRNA in the organism is enhanced. In one 
embodiment, the organism is a mammal. In another embodi 
ment, the organism is a human. In certain embodiments, the 
human has spinal muscular atrophy (SMA). 
[0026] Another embodiment of the invention is directed to 
a method of treating spinal muscular atrophy (SMA) in a 
patient, comprising administering to the patient an oligo 
nucleotide of the invention (e.g., an oligoribonucleotide) in a 
dose effective to enhance the level of exon 7-containing 
SMN2 mRNA relative to exon-deleted SMN2 mRNA in cells 
of the patient, such that SMA in the patient is treated. 
[0027] A further embodiment is directed to a method for 
inhibiting an SMN2 pre-mRNA intronic splicing silencer site 
in a cell or cell extract comprising contacting the cell With an 
oligonucleotide of the invention (e.g., an oligoribonucle 
otide), such that the SMN2 intronic splicing silencer site is 
inhibited. In a related embodiment, the instant invention is 
directed to a method for inhibiting an SMN2 pre-mRNA 
intronic splicing silencer site in an organism comprising 
administering to the organism an oligonucleotide of the 
invention, such that the SMN2 intronic splicing silencer site is 
inhibited. Another embodiment is directed to a method for 
inhibiting an SMN2 pre-mRNA intronic splicing silencer site 
in a subject With SMA comprising administering to the sub 
ject an oligonucleotide of the invention (e.g., an oligoribo 
nucleotide), such that the SMN2 intronic splicing silencer site 
is inhibited. 
[0028] An additional aspect of the invention is directed to a 
method for identifying a protein that interacts With the 
sequences set forth as herein, SEQ ID NOS:2 -5, comprising 
contacting a cell or cell extract With the sequence under 
conditions suf?cient for the sequence to interact With a pro 
tein in the cell or cell extract; and isolating the sequence and 
interacting protein, such that the protein that interacts With the 
target sequence is identi?ed. In one embodiment, the method 
further comprises UV-crosslinking the sequence to the inter 
acting protein. In an additional embodiment, the cell or cell 
extract is of mammalian origin. In certain embodiments, the 
cell or cell extract is of human origin. 
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[0029] Another aspect of the invention is directed to a 
method of enhancing the level of exon 7-containing SMN2 
mRNA relative to exon-deleted SMN2 mRNA in a cell or cell 
extract, comprising contacting the cell or cell extract With an 
oligonucleotide or nucleotide targeted blocking agent of the 
invention, such that the level of exon 7-containing SMN2 
mRNA relative to exon-deleted SMN2 mRNA in the cell or 
cell extract is enhanced. A related aspect of the invention is 
directed to a method of enhancing the level of exon 7-con 
taining SMN2 mRNA relative to exon-deleted SMN2 mRNA 
in an organism, comprising contacting the organism With an 
nucleotide SNM2 blocking agent, such that the level of exon 
7-containing SMN2 mRNA relative to exon-deleted SMN2 
mRNA in the organism is enhanced. 
[0030] In one embodiment, the blocking agent is selected 
from the group consisting of a small molecule, a peptide, a 
polynucleotide, an antibody or biologically active portion 
thereof, a peptidomimetic, and a non-peptide oligomer. In an 
additional embodiment, the blocking agent is a small mol 
ecule. 
[0031] In an additional aspect, the invention is directed to a 
method of treating amyotrophic lateral sclerosis (ALS) in a 
patient, comprising administering to the patient the oligo 
nucleotide of the invention in a dose effective to enhance the 
level of exon 7-containing SMN2 mRNA relative to exon 
deleted SMN2 mRNA in cells of the patient. 
[0032] In an additional embodiment, the oligonucleotide 
reagent of the invention is a riboZyme. 
[0033] Other features and advantages of the invention Will 
be apparent from the folloWing detailed description and 
claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0034] FIG. 1. An ultra-re?ned antisense micro-Walk 
reveals the signi?cance of a cytosine residue at the 10th posi 
tion (10C) of SMN2 exon 7. (A) Diagrammatic representation 
of cis-elements at the 5' end of SMN2 intron 7. ISS-N1 is 
highlighted in yelloW With all but the ?rst nucleotide shoWn in 
red. TWo hnRNP Al motifs are indicated as described in (Hua 
et al. 2008). GC-rich sequence is highlighted in green (Singh 
et al. 2009). Numbering of nucleotides starts from the ?rst 
position of SMN2 intron 7. The location of 10C is marked by 
an arroW. (B) Diagrammatic representation of ASOs and their 
annealing positions relative to ISS-N1 region. Numbering of 
nucleotides starts from the ?rst position of intron 7. Bound 
aries of ISS-N1 are demarcated. The ?rst ISS-N1 residue, 
10C, is highlighted in blue. The GC-rich sequence (Singh et 
al. 2009) is highlighted in green. The core sequence of the 
antisense target is highlighted in yelloW. ASOs are shoWn as 
horizontal bars. Green bars represent ASOs that promote 
SMN2 exon 7 inclusion (exon 7 skipping is 45% and less). 
The intensity of green color re?ects the strength of ASO 
stimulatory effect. Grey bars represent ASOs that have no 
effect on SMN2 exon 7 inclusion. Pink bars represent ASOs 
that promoted SMN2 exon 7 skipping (exon 7 skipping is 
55% and more). To emphasiZe that L14 caused the most 
dramatic increase in exon 7 skipping, it is shoWn as a dark 
pink bar. (C) Splicing pattern of endogenous SMN2 after 
treatment With ASOs shoWn in panel B. SMA type I patient 
?broblasts (GM03813) Were treated With 20 nM of different 
ASOs and the total RNA for in vivo splicing assay Was iso 
lated 24 h post transfection. The upper band corresponds to 
exon 7-included product; the loWer band corresponds to exon 
7-skipped product. The percentage of exon skipping Was 
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calculated from the total value of exon-included and exon 
skipped products. The values represent mean of three inde 
pendent experiments. The standard deviations Were less than 
5% of mean. The effect of P14 and L14 are highlighted With 
green and red box, respectively. (D) Splicing pattern of 
endogenous SMN2 after treatment With 50 nM of indicated 
ASOs. The chemistry of the ASOs used is shoWn on the right. 
In vivo splicing assays Were performed and analyZed as 
described in panel C. The values represent mean of three 
independent experiments. The standard deviations Were less 
than 5% of mean. 
[0035] FIG. 2. Effect of ASOs are speci?c to their targets. 
(A) Diagrammatic representation of the target area in intron 7 
of SMN2 minigene. ISS-N1 is highlighted in light gray. Num 
bering of nucleotides starts from the ?rst position of intron 7. 
The location of 10C is marked by an arroW. The sequences of 
fourASOs and their annealing positions in ISS-N1 region are 
shoWn. Mutations are indicated in White letters and high 
lighted in black. Effect of ASOs on splicing of SMN2 mini 
gene is shoWn on the right. HeLa cells Were co-transfected 
With 50 nM of a given ASO and 0.1 pg of SMN2 minigene. 
Splicing Was determined 24 h after transfection. The percent 
age of exon 7 skipping Was calculated as described in FIG. 
1C. (B) Diagrammatic representation of the target area in 
intron 7 of SMN2/I7-08 minigene. ISS-N1 is highlighted in 
gray. Numbering of nucleotides starts from the ?rst position 
of intron 7. Location of 10C is marked by an arroW. Sequences 
of four ASOs and their annealing positions are shoWn. Muta 
tions in ISS-N1 area as Well as in the ASOs are indicated in 
White letters and highlighted in black. Effect of the ASOs on 
splicing of SMN2/I7-08 minigene is shoWn on the right. In 
vivo splicing assays Were performed and analyZed as 
described in panel A. 
[0036] FIG. 3. Sequestration of 1OC decides the outcome of 
antisense response. Numbering of nucleotides starts from the 
?rst intronic position. ISS-N1 sequence is highlighted in grey. 
The ?rst C residue in ISS-N1 is marked as 10C (A) Diagram 
matic representation of the 5' portion of intron 7 of SMN2 
minigene and its mutant, SMN2/A64. The location of 1OC and 
its deletion are indicated. Effect of ASOs on splicing of Wild 
type and mutated SMN2 minigene is shoWn on the right. 
Co-transfections and analyses Were done as in (FIG. 2A). (B) 
Diagrammatic representation of Wild type and mutated ISS 
N1 targeted by different ASOs. Sequences of ASOs and their 
base pairing With the corresponding target are shoWn. Note 
that Wild type and mutated ISS-N1 element are located Within 
intron 7 of SMN2 and SMN2/64A minigene, respectively. 
ArroWs mark 1OC and 10A positions. The 3'-overhang of 
ASOs are highlighted. Effect of ASOs on splicing of SMN2 
mini gene and its mutant, SMN2/ 64A, is shoWn in the bottom 
panel. Co-transfections and splicing analyses Were done as in 
(FIG. 2A). 
[0037] FIG. 4. Effect of the local context on antisense 
response of ISS-N1-targeting ASOs. (A) Diagrammatic rep 
resentation of the target area in intron 7 of SMN2 minigene 
and its four mutants. ISS-N1 is highlighted in grey. The ?rst 
C residue in ISS-N1 is marked as 10C or 15C depending on its 
position relative to the beginning of intron 7. Of note, num 
bering of intronic residues starts With the ?rst position of 
intron 7. Five-nucleotide-long insertions immediately 
upstream of ISS-N1 in SMN2/ 5A or SMN2/ 5G minigenes are 
boxed and shoWn in capital letters. (B) In vivo splicing pattern 
of Wild type and mutant SMN2 minigenes shoWn in panel A. 
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The minigenes Were co-transfected With an ASO of interest. 
Co-transfections and splicing analysis Were done similarly as 
in (FIG. 2A). 
[0038] FIG. 5. Effect of the heterologous context on anti 
sense response of ISS-Nl -targeting ASOs. (A) Diagrammatic 
representation of exon 6/intron 6 junction in Casp3 minigene 
variants. 3'-Cluster and ISS-Nl, Which are shaded in grey, 
Were inserted either individually or together 3-nucleotide 
upstream and 9-nucleotide downstream of the exon/intron 
junction, respectively. In Casp3-SMN5'-1 minigene the entire 
region from the beginning of 3'-Cluster to the end of ISS-Nl 
corresponds to SMN sequence. The last three nucleotides of 
SMN exon 7 and the ?rst nine nucleotides of SMN intron 7 are 
highlighted in black. As a result of this insertion, Casp3 exon 
6 noW has the 5' ss of SMN exon 7 folloWed by ISS-Nl 
element. The location of 10C is marked by an arroW. (B) Effect 
of 3'-Cluster and ISS-Nl insertions on Casp3 exon 6 splicing. 
HeLa cells Were transfected With 0.8 pg of Casp3 minigene 
variant and the total RNA for in vivo splicing assay Was 
isolated 24 h post transfection. Exon 6-included and exon 
6-skipped spliced products are indicated. Percentage of exon 
skipping Was calculated from the total value of exon-included 
and exon-skipped products similarly as in FIG. 2. (C) In vivo 
splicing patterns of tWo Casp3 minigene variants in the pres 
ence of ASOs. Co-transfections and splicing analysis Were 
done as in FIG. 2A. (D) In vivo splicing patterns of 
Casp3SMN2 minigene in the presence of ASOs. Diagram 
explaining the composition of this hybrid minigene is shoWn 
on the top. Co-transfections and splicing analysis Were done 
as in panel C. 
[0039] FIG. 6. Effect of deletions Within intron 6 and intron 
7 on antisense response of ISS-Nl -targeting ASOs. (A) Dia 
grammatic representation of the deleted regions in intron 6 
and 7 of SMN2 minigene. Deletions are represented by dotted 
lines. Positive numbers indicate nucleotide positions Within 
intron 7 and start from the ?rst position of this intron. Nega 
tive numbers indicate nucleotide positions Within intron 6 and 
start from the last position of this intron. Names of mutants 
are given on the left; numbers in names re?ect positions of the 
?rst and the last deleted nucleotides. A deletion mutant pro 
ducing a stimulatory effect in presence of anASO is shoWn as 
plus, Whereas a mutant producing a negative effect in pres 
ence of anASO is shoWn as minus. (B) In vivo splicing pattern 
of Wild type and mutant SMN2 minigenes shoWn in panel A. 
Minigenes Were co-transfected With an ASO of interest. Co 
transfections and splicing analyses Were done similarly as in 
FIG. 2A. 
[0040] FIG. 7. Effect of deletions Within intron 7 on anti 
sense response of ISS-Nl -targeting ASOs. (A) Diagrammatic 
representation of the deleted regions Within intron 7 of SMN2 
mini gene. Deletions are represented by dotted lines. Numbers 
indicate nucleotide positions and start from the ?rst position 
of intron 7. Names of mutants are given on the left; numbers 
in the names re?ect positions of the ?rst and the last deleted 
nucleotides.A deletion mutant producing a stimulatory effect 
in presence of an ASO is shoWn as plus, Whereas a mutant 
producing a negative effect in presence of anASO is shoWn as 
minus. (B) In vivo splicing pattern of mutant SMN2 mini 
genes shoWn in panel A. Minigenes Were co-transfected With 
an ASO of interest. Co-transfections and splicing analysis 
Were done similarly as in FIG. 2A. 
[0041] FIG. 8. Site-speci?c UV-crosslinking of puri?ed 
recombinant hnRNP A1 With ISS-Nl. (A) Puri?cation of 
recombinant hnRNP A1 protein expressed from pTXB3-A1 
Nov. 3, 2011 
in E. coli ER2566 strain. Protein Was puri?ed by binding to a 
chitin af?nity column, folloWed by DTT-induced self-cleav 
age of the Mycobaclerium xenopi GyrA intein. Sample ali 
quots Were collected at different puri?cation steps and used 
for SDS-polyacrylamide gel electrophoresis. Lane 1, molecu 
lar Weight markers; lane 2, clari?ed lysate; lane 3, ?oW 
through from the column; lanes 4 & 5, Wash With increasing 
concentration of NaCl; lane 6, DTT ?ush; lane 7, pooled 
hnRNP A1-containing fractions eluted after overnight DTT 
induced intein self-cleavage at 40 C. Band corresponding to 
hnRNP A1 is indicated by an arroW. Right panel shoWs the 
diagrammatic representation of pTXB3-A1 construct. This 
construct contains hnRNP A1 ORF With a C-terminus fused 
in frame to the Mycobaclerium xenopi GyrA intein/chitin 
binding domain (CBD). (B) Diagrammatic representation of 
steps for site-speci?c 32P-labeling of RNA probe. The 
sequence of probe and its relative location Within SMN are 
given. ISS-Nl is highlighted in yelloW and its sequence 
shoWn in red letters. Position of the 32P-radioisotope incor 
poration is indicated by a star. The sequence of the bridging 
DNA oligonucleotide is shoWn in green. (C) Autoradiogram 
shoWing hnRNP A1-crosslinked product. Site-speci?cally 
32P-labeled RNA probe Was UV-crosslinked With puri?ed 
recombinant hnRNP A1 folloWed by RNase digestion and 
fractionation on 13% SDS-polyacrylamide gel. (D) 
UV-crosslinking in the presence of different ASOs under 
“denaturing” condition. Here, RNA probe Was ?rst refolded 
in the presence of a corresponding ASO to insure ASO 
annealing. After that the puri?ed hnRNP Al was added to the 
reaction mixture folloWed by UV-crosslinking. Analysis of 
hnRNP A1-crosslinked products Was done as in panel C. (E) 
UV-crosslinking in the presence of different ASOs under 
“native” condition. Here the RNA probe Was denatured and 
refolded prior to an ASO and hnRNP A1 addition to the 
reaction mixture. UV-crosslinking reaction and analysis of 
the products Were performed as in panel C. 
[0042] FIG. 9. Model of SMN2 exon 7 splicing modulation 
by 10C in the presence ofL14 and F14. (A) L14 PathWay: L14 
leaves l0C unsequestered and accessible for a long-distance 
interaction With intronic sequences upstream of the branch 
point. This arrangement interferes With the catalytic core 
formation at the 5' ss of exon 7. Consequently, the competing 
5' ss of exon 6 becomes the favorable substrate for the trans 
esteri?cation reaction leading to exon 7 skipping. (B) F14 
PathWay: F14 sequesters 1OC and prevents a long-distance 
interaction With intronic sequences upstream of the branch 
point. This arrangement favors catalytic core formation at the 
5' ss of exon 7. Consequently, SMN2 exon 7 inclusion is 
promoted. 
[0043] FIG. 10 is a diagram shoWing intron 7 and the long 
distance target sites for additional oligos. 
[0044] FIG. 11. Ultra-re?ned antisense microWalk to iden 
tify the shortest stimulatory ASO. (A) Diagrammatic repre 
sentation of ASOs targeting sequences upstream of ISS-Nl. 
Exon 7 is boxed and the ?rst 24 residues of human SMN 
intron 7 are shoWn. Numbering starts from the ?rst position of 
intron 7. The 5' ss of exon 7 is indicated by a vertical arroW. 
ASOs blocking different regions are shoWn as horizontal 
bars. Sequences of these ASOs are given in Table A. Bound 
ary of ISS-Nl is demarcated. hnRNPA1 motifs are indicated. 
Green bars represent ASOs that promote SMN2 exon 7 inclu 
sion. Intensity of green color re?ects the strength of stimula 
tory effect. Tan bars represent ASOs that have no effect on 
SMN2 exon 7 inclusion. Area highlighted in pink represents 








































